PK/PD modelling is an important aspect of dose prediction of antibiotics for both preclinical and clinical development and is a requirement of the EMA and FDA. This technique facilitates efficient dose-response study designs and assists in identifying optimal dosing regimens to ensure clinical efficacy and to suppress drug resistance. Cyprotex is increasingly supporting its parent company, Evotec, in the modelling and simulation area. For example, mathematical modelling techniques have been applied in the rational design of antibiotic efficacy studies to reduce the number of animals required to determine the magnitude of efficacy and pharmacodynamic driver and promote acceptance of such data by regulatory authorities.
Our research was presented at the Alderley Park 3R’s Poster Event on 17th October 2018. The event was jointly hosted by AstraZeneca, Cancer Research UK and Agenda Life Sciences. The poster was awarded 1st prize in the event for its contribution to the 3R’s concept of Replacement, Reduction and Refinement.